Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria -: A population-based study

被引:301
作者
Traynor, BJ
Codd, MB
Corr, B
Forde, C
Frost, E
Hardiman, OM
机构
[1] Beaumont Hosp, Dept Neurol, Dublin 9, Ireland
[2] Mater Misericordiae Univ Hosp, Dept Epidemiol & Biostat, Dublin 7, Ireland
[3] Irish Motor Neuron Dis Assoc, Dublin, Ireland
关键词
D O I
10.1001/archneur.57.8.1171
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The El Escorial and the revised Airlie House diagnostic criteria for amyotrophic lateral sclerosis (ALS) classify patients into categories reflecting different levels of diagnostic certainty. We conducted a prospective, population-based study of the natural course of ALS in the Republic of ireland during a 6-year period to examine the utility of these ALS diagnostic criteria. Methods: Using data from the Irish ALS Register, we studied the clinical features of all patients diagnosed as having ALS in Ireland throughout their illness. Results: Between 1993 and 1998, 388 patients were diagnosed as having ALS. Forty percent of patients reported bulbar-onset symptoms. Disease progression occurred over time: at last follow-up, 75% of all patients had bulbar signs, compared with 59% at diagnosis. When the Fl Escorial criteria were applied, more than half of patients (218 [56% ]) had definite or probable ALS at diagnosis. Of the 165 possible and suspected ALS cases at diagnosis (trial ineligible), 110 (67%) were trial eligible at last follow-up. Of the 254 patients who had died, 229 (90%) had definite or probable ALS, whereas 25 patients (10%) remained trial ineligible at death. El Escorial category at diagnosis was not a significant prognostic indicator. Use of the Airlie House criteria had no effect on the median time from symptom onset to trial eligibility (12.9 vs 12.8 months). Conclusions: The El Escorial and Airlie House diagnostic criteria are excessively restrictive. Furthermore, levels of diagnostic certainty cannot he used as prognostic indicators.
引用
收藏
页码:1171 / 1176
页数:6
相关论文
共 29 条
[1]   Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia [J].
Andersen, PM ;
Nilsson, P ;
Keranen, ML ;
Forsgren, L ;
Hagglund, J ;
Karlsborg, M ;
Ronnevi, LO ;
Gredal, O ;
Marklund, SL .
BRAIN, 1997, 120 :1723-1737
[2]  
Armon C, 1999, MUSCLE NERVE, V22, P1571, DOI 10.1002/(SICI)1097-4598(199911)22:11<1571::AID-MUS13>3.3.CO
[3]  
2-S
[4]   A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis [J].
Borasio, GD ;
Robberecht, W ;
Leigh, PN ;
Emile, J ;
Guiloff, RJ ;
Jerusalem, F ;
Silani, V ;
Vos, PE ;
Wokke, JHJ ;
Dobbins, T .
NEUROLOGY, 1998, 51 (02) :583-586
[5]   Electrodiagnostic studies in clinical trials for motor neuron disease [J].
Bromberg, MB .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 1998, 15 (02) :117-128
[7]   THE PROGNOSIS OF ADULT-ONSET MOTOR-NEURON DISEASE - A PROSPECTIVE-STUDY BASED ON THE SCOTTISH MOTOR-NEURON DISEASE REGISTER [J].
CHANCELLOR, AM ;
SLATTERY, JM ;
FRASER, H ;
SWINGLER, RJ ;
HOLLOWAY, SM ;
WARLOW, CP .
JOURNAL OF NEUROLOGY, 1993, 240 (06) :339-346
[8]  
CHAUDHURI KR, 1995, J NEUROL SCI, V129, P11
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   COMMENT ON THE LOWER MOTOR-NEURON HYPOTHESIS [J].
EISEN, AA .
MUSCLE & NERVE, 1993, 16 (08) :870-872